Analyst Price Target is $7.00
▲ +215.32% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for PetVivo in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 215.32% upside from the last price of $2.22.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in PetVivo.
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.